#Technivie

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.

A recent study tested the effectiveness and tolerability of Technivie (ombitasvir/paritaprevir/ritonavir) among those over 65.

This was among a small group of people who contracted the virus within one year, most of whom had HIV as well.

The triple-drug regimen comes in a once-daily single tablet.

FDA warns of risk of hepatitis B virus reactivation in patients coinfected with hepatitis C virus and hepatitis B virus.

The FDA has required AbbVie to add warnings to two of its HCV treatments after receiving reports of serious liver damage.

What I did not anticipate was that the panel would make off-label recommendations for daclatasvir.